Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

ARIX.L (ARIX) Share News

DIRECTOR DEALINGS: M&G chair and new CEO buy GBP450,000 in shares

10th Oct 2022 15:42

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Monday and last week and not separately reported by Alliance News: Read More

IN BRIEF: Arkle Resources restarts drilling at Stonepark project

15th Sep 2022 12:10

Arkle Resources PLC - Ireland-based gold and zinc explorer - Says that Group Eleven Resources Corp, its partner and operator for the Stonepark project located near Limerick, Ireland, said that it restarted drilling. Plans to drill the next drill hole on PL3367, roughly 12 kilometres southwest of the Stonepark deposit. Expects all drilling to be completed by year-end. Read More

Arix Bioscience NAV falls; portfolio firm Disc to merge with Gemini

12th Aug 2022 07:01

(Alliance News) - Arix Bioscience PLC on Thursday reported a decline in net asset value as public biotech markets did not perform well. Read More

UK earnings, trading statements calendar - next 7 days

3rd Aug 2022 15:57

UK shareholder meetings calendar - next 7 days

31st May 2022 16:03

TRADING UPDATES: Enwell pleased with SV-31; SDX Energy ties in well

6th May 2022 19:11

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More

EARNINGS UPDATES: Taseko swings to profit; Directa Plus loss narrows

5th May 2022 16:58

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

IN BRIEF: Arix Bioscience says Harpoon ends prostate cancer study

15th Mar 2022 08:34

Arix Bioscience PLC - London-based venture capital investor in biotech firms - Notes that portfolio company Harpoon Therapeutics Inc discontinued its phase 1/2 dose-escalation study for HPN424, a treatment for advanced prostate cancer, following a thorough analysis of its HPN424 data. The decision will allow Harpoon to concentrate on HNP328, a treatment in development for tumours associated with delta-like ligand 3 expression, and on HPN 217 for BCMA, an important therapeutic target in the treatment of multiple myeloma. Read More